Plain-English translation of NCT03311776 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Pancreatic Cancer research guide →The BIOPAC study is looking for biological markers—special signals in your blood—that could help doctors detect pancreatic cancer earlier and predict how well your treatment will work. Researchers will collect blood samples from you at different times (before surgery or chemotherapy and during treatment) along with information about your health and how you respond to treatment.
Pancreatic cancer is very difficult to catch early, and survival rates haven't improved much in recent years. Right now, doctors don't have reliable blood tests to identify pancreatic cancer at an early stage or to predict which treatments will work best for individual patients. This study aims to discover those markers so future patients can be diagnosed sooner and treated more effectively.
You likely qualify if…
You likely don't qualify if…
You will give blood samples before your surgery or chemotherapy starts, then again before your second round of chemotherapy and whenever you have imaging scans until your disease progresses. The study team will also collect routine information about your health, your treatment, and how you respond to it. You will be followed over time, even if your cancer comes back or you switch to different treatments, and the study continues to collect data throughout your care.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
Denmark
Enrollment target
~5,000 participants
Started
July 2008
Primary completion
July 2035
Age range
19 Years and older
Last updated on clinicaltrials.gov in March 2023.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Julia Sidenius Johansen, MD, DMsc
Inna Chen, MD
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.